top
Please input keywords
Biocytogen to Present Progress of Antibody Assets and Five Fully Human Antibody Discovery Platforms at ChinaBio 2022
2022.11.03


Biocytogen’s BD & Licensing team will attend and present at the upcoming ChinaBio virtual conference on November 8-11, 2022.


from clipboard


The company will give an oral presentation with the title of “Introduction of Biocytogen’s pipeline assets, innovative fully human antibody RenMice platform and Project Integrum for antibody discovery against 1000+ potential targets”. The talk will introduce Biocytogen’s clinical asset YH003 (CD40 antibody) and preclinical assets YH008 (PD-1×CD40 BsAb), YH006 (CTLA-4×OX40 fully human BsAb) and YH013 (EGFR×MET BsADC). The talk will also highlight the latest progress of Project Integrum and introduce the company’s five proprietary RenMiceTM-based fully human antibody discovery platforms, which are designed to facilitate the discovery of monoclonal antibodies, bispecific antibodies, bispecific ADCs, TCR-mimic antibodies and antibodies targeting GPCRs. In addition, the company's flexible business collaboration models and collaboration progress will be introduced.


Biocytogen’s attendees will also host one-on-one partnering meetings. Our experts look forward to discussing licensing and co-development opportunities with you.

For questions, please contact us at BD-Licensing@biocytogen.com.


To reserve a one-on-one meeting with us via PartneringONE, click here.

Log in to watch the presentation (only in English), click here.